Advertisement
The study is needed because of the dismally low survival rates for cardiacarrest; the national average for surviving such a cardiac arrest that occursoutside a hospital setting is only one in twenty.
Advertisement
The NIH funding will be used to increase enrollment in the six-site study.The study involves the testing of the ResQPump(R) an activecompression/decompression device, in combination with the ResQPOD(R), a deviceused to increase blood flow to the heart and brain during CPR. The ResQPOD, animpedance threshold device proven to increase circulation, has previouslyreceived clearance from the FDA and is in use at more than 1,100 customer sitesin the US. The current NIH funded study is the first randomized study in the USto assess results of the ResQPump and ResQPOD used together and comparingresults when CPR is performed without these devices. The ResQPump has beentested and is currently in use in Europe. Both devices are designed andmanufactured by Advanced Circulatory Systems of Minneapolis, MN.
The six sites involved in the study include Minneapolis, MN; St. Paul, MN;Whatcom County, WA; Oshkosh, WI; suburban Detroit including parts of Oakland andMacomb counties, MI; and Livingston County, MI which includes the city of AnnArbor.
The use of new technologies as well as improved CPR procedures asrecommended by the American Heart Association in its latest guidelines areintended to help more people survive a cardiac arrest and with their brainfunction intact. Studies like the NIH funded study are believed to be amongthe best methods to prove how treatments can impact outcomes.
Advanced Circulatory Systems' mission is to restore life and improve thequality of life for patients suffering cardiac arrest, low blood pressure andhead injury by developing new technologies to non-invasively increasecirculation throughout the body, providing improved opportunity for survival andquality of life. The privately held company is based in Minneapolis, MN.
Media contact: Joanne Henry, 612-843-2142, [email protected]
Advanced Circulatory Systems medical contact: Keith Lurie, M.D., ChiefMedical Officer, 952-947-9590, [email protected]
The generally cleared indication for the ResQPOD is a temporary increase inblood circulation during emergency care, hospital, clinic and home use. Studiesare ongoing in the United States to evaluate the long-term benefit of theResQPOD for indications related to patients suffering from cardiac arrest,hypotension during dialysis and severe blood loss. The references in thiscommunication are not intended to imply specific outcome-based claims not yetcleared by the US Food and Drug Administration. Clinical study references areavailable upon request.
SOURCE Advanced Circulatory Systems, Inc.
